MMP3 and Parkinson disease: In Parkinson’s disease patients, SATB1 (a CDKN1A inhibitor) levels are reduced in the substantia nigra, while CDKN2A, MMP3, IL-6, IL-1α, and CXCL8 levels are elevated, indicating an increased aging burden (96).